Maat Pharma SA (MAAT)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 1.000 |
|---|---|
| 52-week range | 0.903 – 8.620 |
| Return, 1 month / 3 months | −38.7% / −63.4% |
| Return, 1 year / 3 years | −76.9% / −87.5% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 144.6% |
| Worst drawdown (1 year) | -88.3% |
| Average daily value traded | 0.15M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MaaT Pharma is a French biopharmaceutical company based in Lyon that develops therapies built around the human gut microbiome. Its work centres on microbiome ecosystem therapies, which use donated faecal material processed into standardized medicinal products, and it also develops related technologies for collecting and manufacturing these treatments. The company's programmes target serious conditions affecting cancer patients and others whose gut bacteria have been disrupted, and it works with hospital clinicians and research partners on clinical studies of its candidates.
The shares are listed on the Euronext Paris in France under the code MAAT, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Maat Pharma SA (MAAT) trades on the Euronext Paris in France. It last closed at EUR 1.000 on 19 October 2026.
Its price-based Market X-Ray is 13 out of 100 (a weak price profile), ranking 605 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 76.9% and over the last three months it fell 63.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 2 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -76.7% | ||
| From 52-week high | -87.1% | ||
| Momentum | 3 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -63.4% | ||
| 6-month return | -81.1% | ||
| 12-month return, skipping the last month | -62.3% | ||
| Stability (higher is calmer) | 3 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 144.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -88.3% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.15M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +10.1% |
|---|---|
| 1 month | −38.7% |
| 3 months | −63.4% |
| 6 months | −81.1% |
| 1 year | −76.9% |
| 3 years | −87.5% |
| 5 years | −92.6% |
Signals
| 50-day / 200-day average | 2.036 / 4.285 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.123 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.